• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

感染前或既往感染者接种 1 剂和 2 剂 BNT162b2 疫苗后的 SARS-CoV-2 抗体反应。

SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine.

机构信息

Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, Illinois.

Division of Allergy and Immunology, Department of Internal Medicine, Rush University Medical Center, Rush University, Chicago, Illinois.

出版信息

JAMA Netw Open. 2021 Aug 2;4(8):e2119741. doi: 10.1001/jamanetworkopen.2021.19741.

DOI:10.1001/jamanetworkopen.2021.19741
PMID:34357399
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8346938/
Abstract

This cohort study examines antibody responses in infection-naive and previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine.

摘要

本队列研究考察了感染前和既往感染者在接种 1 剂和 2 剂 BNT162b2 疫苗后的抗体反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9198/8346938/3371d2162ae4/jamanetwopen-e2119741-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9198/8346938/3371d2162ae4/jamanetwopen-e2119741-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9198/8346938/3371d2162ae4/jamanetwopen-e2119741-g001.jpg

相似文献

1
SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine.感染前或既往感染者接种 1 剂和 2 剂 BNT162b2 疫苗后的 SARS-CoV-2 抗体反应。
JAMA Netw Open. 2021 Aug 2;4(8):e2119741. doi: 10.1001/jamanetworkopen.2021.19741.
2
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
3
Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals.在先前感染过的个体中，第一剂后一周内和未感染个体中第二剂后，BNT162b2 mRNA 疫苗会引发强烈的抗体反应。
Front Immunol. 2021 Aug 26;12:722766. doi: 10.3389/fimmu.2021.722766. eCollection 2021.
4
Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).医护人员接种两剂 SARS-CoV-2 mRNA 疫苗（BNT162b2）后的早期抗体反应。
Clin Microbiol Infect. 2021 Sep;27(9):1351.e5-1351.e7. doi: 10.1016/j.cmi.2021.05.004. Epub 2021 May 8.
5
Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations.SARS-CoV-2 既往感染人群和未感染人群接种 BNT162b2 mRNA 疫苗的安全性和体液免疫应答。
Sci Rep. 2021 Aug 16;11(1):16543. doi: 10.1038/s41598-021-96129-6.
6
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
7
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers.接种 BNT162b2 疫苗 3 个月后抗 SARS-CoV-2 抗体反应的动力学；283 名卫生工作者的前瞻性研究。
Cells. 2021 Jul 30;10(8):1942. doi: 10.3390/cells10081942.
8
Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).肾移植受者对 BNT162b2（辉瑞-生物科技）接种 SARS-CoV-2 疫苗的体液免疫反应受损。
Viruses. 2021 Apr 25;13(5):756. doi: 10.3390/v13050756.
9
One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19.一剂 SARS-CoV-2 疫苗可使从有症状的 COVID-19 中康复的个体的抗体呈指数级增长。
J Clin Invest. 2021 Jun 15;131(12). doi: 10.1172/JCI149154.
10
Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.接种BNT162b2 mRNA疫苗后，医护人员和八旬老人针对新冠病毒的年龄和性别依赖性抗体反应。
Am J Hematol. 2021 Jul 1;96(7):E257-E259. doi: 10.1002/ajh.26185. Epub 2021 Apr 24.

引用本文的文献

1
Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China.比较吸入式Ad5-nCoV疫苗异源加强针与混合免疫对奥密克戎BA.5感染的保护作用：一项针对中国医院工作人员的队列研究。
BMC Infect Dis. 2024 Dec 18;24(1):1401. doi: 10.1186/s12879-024-10250-1.
2
Dynamics of anti-SARS-CoV-2 antibodies in the Albanian population: Impact of infection- and vaccine-induced immunity during the COVID-19 pandemic.阿尔巴尼亚人群中抗SARS-CoV-2抗体的动态变化：新冠疫情期间感染和疫苗诱导免疫的影响
IJID Reg. 2024 Sep 5;13:100440. doi: 10.1016/j.ijregi.2024.100440. eCollection 2024 Dec.
3

本文引用的文献

1
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.单剂 SARS-CoV-2 mRNA 疫苗后的抗体反应。
N Engl J Med. 2021 May 20;384(20):1959-1961. doi: 10.1056/NEJMc2102051. Epub 2021 Mar 23.
2
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.既往感染过严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的个体对第一剂BNT162b2的抗体反应。
Lancet. 2021 Mar 20;397(10279):1057-1058. doi: 10.1016/S0140-6736(21)00501-8. Epub 2021 Feb 25.
3
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
含 AS03 佐剂的二价（D614G+B.1.351）SARS-CoV-2 重组蛋白疫苗在成年人中的效力：一项 3 期、平行、随机、修改的双盲、安慰剂对照试验。
Lancet Respir Med. 2023 Nov;11(11):975-990. doi: 10.1016/S2213-2600(23)00263-1. Epub 2023 Sep 13.
4
Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis.老龄化对 COVID-19、HIV 和结核病背景下免疫的影响。
Front Immunol. 2023 May 24;14:1146704. doi: 10.3389/fimmu.2023.1146704. eCollection 2023.
5
Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose.新冠疫苗接种者的长期适应性反应和加强针的效果。
Front Immunol. 2023 Feb 28;14:1123158. doi: 10.3389/fimmu.2023.1123158. eCollection 2023.
6
Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.评估 BNT162b2 初级接种后 9 个月对 SARS-CoV-2 的剩余体液免疫应答的替代病毒中和试验（sVNT）。
J Infect Chemother. 2023 Jun;29(6):624-627. doi: 10.1016/j.jiac.2023.03.002. Epub 2023 Mar 11.
7
Evolution of antibody profiles against SARS-CoV-2 in experienced and naïve vaccinated elderly people.有经验和无经验的老年疫苗接种者对 SARS-CoV-2 的抗体谱演变。
Front Immunol. 2023 Feb 22;14:1128302. doi: 10.3389/fimmu.2023.1128302. eCollection 2023.
8
COVID-19 Vaccination in Kidney Transplant Recipients: An Ounce Pre-Transplant is Worth a Pound Post-Transplant.肾移植受者的新冠病毒疫苗接种：移植前预防一分，胜过移植后治疗十分。
J Am Soc Nephrol. 2021 Dec 1;32(12):2977-2978. doi: 10.1681/ASN.2021101347.
9
Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment.基于与替代病毒中和抗体检测和临床评估的比较，评价 Ortho VITROS SARS-CoV-2 刺突蛋白特异性定量 IgG 检测的性能。
PLoS One. 2023 Jan 24;18(1):e0279779. doi: 10.1371/journal.pone.0279779. eCollection 2023.
10
Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India.在完全接种Covishield（AZD1222）和Covaxin（BBV-152）疫苗的受种者中抗SARS-CoV-2 IgG抗体反应：一项在印度西孟加拉邦南部开展的研究
Iran J Microbiol. 2022 Oct;14(5):611-616. doi: 10.18502/ijm.v14i5.10953.
既往感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对单剂量BNT162b2疫苗体液和T细胞反应的影响
Lancet. 2021 Mar 27;397(10280):1178-1181. doi: 10.1016/S0140-6736(21)00502-X. Epub 2021 Feb 25.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.